Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study

BACKGROUND: 10%–15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease domain mutations, and are characterised by high tumour mutational burden and increased lymphocytic infiltrate. Metastatic dMMR colon cancers a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESMO Open
Egile Nagusiak: Lau, David, Kalaitzaki, Eleftheria, Church, David N, Pandha, Hardev, Tomlinson, Ian, Annels, Nicola, Gerlinger, Marco, Sclafani, Francesco, Smith, Gillian, Begum, Ruwaida, Crux, Richard, Gillbanks, Angela, Wordsworth, Sarah, Chau, Ian, Starling, Naureen, Cunningham, David, Dhillon, Tony
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7046393/
https://ncbi.nlm.nih.gov/pubmed/32079623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000638
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak